Moderna Surges 85% After Success of mRNA Cancer Vaccine in Phase 3

Moderna shares (MRNA) surged between 85% and 125% during the August 19 session, after the company announced the success of the first Phase 3 trial for a messenger RNA (mRNA) cancer vaccine, in an event described as a milestone in the history of treatment using this technology.

This news prompted investors to shift part of their portfolios toward healthcare and pharmaceutical stocks, in a partial sector rotation wave that offset some of the losses incurred by tech stocks during the same period.

This announcement represents a crucial test of mRNA technology's ability to transcend its applications in COVID vaccines and enter the field of actual treatment for chronic diseases such as cancer.

Markets view this event as more than just a company announcement, as it could redraw the trajectory of the entire biotechnology sector if the vaccine is approved and commercialization begins.

What do these terms mean?

mRNA Technology (Messenger RNA): A therapeutic method that provides body cells with temporary genetic instructions to produce proteins that stimulate the immune system — used in COVID vaccines and now being developed to treat cancer.

Phase 3 Trials: The final phase of clinical trials, conducted on thousands of participants to prove efficacy and safety on a large scale before obtaining official marketing approval.

Sector Rotation: The phenomenon of investors shifting between market sectors, such as moving from tech stocks to healthcare stocks, in search of better returns or protection from existing risks.